Market Overview - On February 4, the medical services sector rose by 1.18% compared to the previous trading day, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 32.72, up 8.56%, with a trading volume of 144,400 shares and a transaction value of 464 million [1] - MediX (688202) closed at 63.84, up 3.70%, with a trading volume of 46,200 shares and a transaction value of 289 million [1] - Other notable performers include: - Purui Eye Hospital (301239) at 35.56, up 2.92% [1] - Tigermed (300347) at 64.94, up 2.75% [1] - Kanglong Chemical (300759) at 30.37, up 2.57% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 427 million from institutional investors, while retail investors experienced a net outflow of 439 million [2][3] - Notable net inflows from institutional investors include: - Tigermed (300347) with 158 million [3] - Aier Eye Hospital (300015) with 118 million [3] - WuXi AppTec (603259) with 112 million [3] Individual Stock Capital Flow - Tigermed (300347) had a net institutional inflow of 158 million, accounting for 14.54% of its trading volume [3] - Aier Eye Hospital (300015) had a net institutional inflow of 118 million, representing 12.46% of its trading volume [3] - Other stocks with significant institutional inflows include: - WuXi AppTec (603259) with 112 million [3] - Kanglong Chemical (300759) with 58.6 million [3]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Group 1 - The company HaiTe Bio (300683) responded to investor inquiries on its interactive platform regarding the specific situation of Shaite, directing investors to refer to the company's periodic reports for detailed information [1]

Group 1 - The company, HaiTe Bio (300683), is actively monitoring and valuing the application and development of a specific technology in its research and development efforts [1] - The company will promptly announce any significant matters related to this technology [1]

Core Viewpoint - The company, Haitai Biological (300683.SZ), expects a significant loss in 2025, with projected losses ranging from 170 million to 240 million yuan, and a revenue forecast between 482.1 million and 586.59 million yuan [1] Group 1: Financial Performance - The company's raw materials and intermediates business is facing continuous losses due to intensified market competition and insufficient orders, leading to revenue falling short of expectations [1] - The subsidiary, Hanrui Pharmaceutical (Jingmen) Co., Ltd., has recognized an inventory impairment loss of approximately 11.93 million yuan due to declining sales prices influenced by market competition [1] - The subsidiary, Tianjin Hankan Pharmaceutical Biotechnology Co., Ltd., is expected to experience a decline in revenue due to market conditions and policy regulations, resulting in indications of goodwill impairment [1] Group 2: Impairment and Provisions - The company has made a cautious decision to recognize a goodwill impairment provision of 85 million yuan related to the acquisition of Tianjin Hankan's equity [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 28 million and 36 million yuan, primarily from investment income and government subsidies [1] - The equity method investment in Westway Pharmaceutical Technology (Shanghai) Co., Ltd. has resulted in a long-term equity investment impairment of 14.99 million yuan [1]

证券代码：300683 证券简称：海特生物 公告编号：2026-011 武汉海特生物制药股份有限公司 本公司以预期信用损失为基础，对应收账款、应收票据、其他应收款进行减 值测试并确认减值损失。经初步测试，2025年度公司拟计提信用减值损失34.90 万元。 关于2025年度拟计提资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假记 载、误导性陈述或者重大遗漏。 一、 本次拟计提资产减值准备情况概述 根据《企业会计准则》及武汉海特生物制药股份有限公司（以下简称"公司"、 "本公司"）会计政策的相关规定，公司合并报表范围内各公司对2025年12月末所 属资产进行了减值测试，基于谨慎性原则，拟对可能发生资产减值损失的相关资 产计提减值准备，预计2025年全年计提资产减值准备金额合计为12,089.99万元， 本次计提资产减值准备情况未经会计师事务所审计。 具体明细如下： 单位：人民币万元 | 项目名称 | 年度拟计提减值准备金额 2025 | | --- | --- | | 1、信用减值损失 | 34.90 | | 其中：应收账款坏账损失 | 48.08 | | 应收票据损失 | ...

Financial Projections - The company expects a net profit loss of between 17,000 and 24,000 million yuan for the year 2025, compared to a loss of 6,934.87 million yuan in 2024[4] - Total profit is projected to be a loss of between 18,000 and 26,000 million yuan, up from a loss of 8,014.06 million yuan in the previous year[4] - Operating revenue is estimated to be between 48,210 and 58,659 million yuan, a decrease from 64,897.41 million yuan in 2024[4] Impairment Losses - The company plans to recognize an impairment loss of approximately 8,500 million yuan on goodwill related to its subsidiary Tianjin Hankan Pharmaceutical Technology Co., Ltd due to expected revenue decline[7] - Inventory impairment losses of about 11.93 million yuan are expected due to increased market competition and insufficient orders in the raw materials and intermediates business[7] Non-Recurring Gains and Losses - The company anticipates a significant impact on net profit from non-recurring gains and losses, estimated between 28 million and 36 million yuan, primarily from investment income and government subsidies[7] Financial Data and Forecast - The company has communicated with its accounting firm regarding the earnings forecast, and there are no disagreements on the forecast[5] - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the 2025 annual report[8] - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the financial data[8] Market Risks - The company is facing risks from market competition and policy adjustments that may affect its revenue and profitability[6]